LIRA reduced liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two-thirds. With LIRA, SHBG levels increased by 19%, and free testosterone decreased by 19%. This evidence concerns the gene SHBG and metabolic dysfunction-associated steatotic liver disease.